NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Forecast & News

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Proteostasis Therapeutics Inc (NASDAQ:PTI) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.25) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.15. View Proteostasis Therapeutics' Earnings History.

Proteostasis Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Proteostasis Therapeutics.

3 equities research analysts have issued 12-month price objectives for Proteostasis Therapeutics' shares. Their forecasts range from $4.00 to $14.00. On average, they anticipate Proteostasis Therapeutics' stock price to reach $8.67 in the next twelve months. This suggests a possible upside of 342.2% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics.

News stories about PTI stock have been trending positive on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Proteostasis Therapeutics.

Proteostasis Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 5,190,000 shares, an increase of 56.8% from the December 15th total of 3,310,000 shares. Based on an average daily volume of 5,450,000 shares, the days-to-cover ratio is presently 1.0 days. Currently, 13.3% of the shares of the company are sold short. View Proteostasis Therapeutics' Current Options Chain.

Some companies that are related to Proteostasis Therapeutics include Syros Pharmaceuticals (SYRS), Cue Biopharma (CUE), Evolus (EOLS), Spectrum Pharmaceuticals (SPPI), Calithera Biosciences (CALA), Recro Pharma (REPH), Avid Bioservices (CDMO), OptiNose (OPTN), Mersana Therapeutics (MRSN), Minerva Neurosciences (NERV), Stemline Therapeutics (STML), Puma Biotechnology (PBYI), Galera Therapeutics (GRTX), CytomX Therapeutics (CTMX) and INDIVIOR PLC/S (INVVY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Rite Aid (RAD), Clearside Biomedical (CLSD), Micron Technology (MU), Syndax Pharmaceuticals (SNDX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Resonant (RESN) and vTv Therapeutics (VTVT).

(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $1.96.

Proteostasis Therapeutics has a market capitalization of $100.21 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe.View Additional Information About Proteostasis Therapeutics.

The official website for Proteostasis Therapeutics is http://www.proteostasis.com/.

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]